The American College of Radiology (ACR) has begun participating in the U.S. Food and Drug Administration's (FDA) Total Product Life Cycle Advisory Program (TAP) pilot.
TAP's goal is to increase radiologist and patient access to safe, effective, and clinically meaningful radiology device innovations, including AI-enabled software. The FDA established it initially to offer input in the areas of patient engagement, clinical evidence development, clinical practice and new technology adoption, and reimbursement and has been limited to certain devices with "Breakthrough Device" designations; it has expanded from solely cardiology devices to neurology, ophthalmology, and radiology devices, the ACR said.













![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)





